Development
GSK plc
GSK
$41.30
$0.441.08%
NYSE
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -3.04% | 14.80% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -3.04% | 14.80% | |||
| Cost of Revenue | 23.13% | 19.47% | |||
| Gross Profit | -12.98% | 13.13% | |||
| SG&A Expenses | 15.89% | -0.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -127.66% | 13.30% | |||
| Total Operating Expenses | 12.53% | 10.30% | |||
| Operating Income | -37.09% | 26.06% | |||
| Income Before Tax | -79.24% | -8.83% | |||
| Income Tax Expenses | -107.25% | 7.42% | |||
| Earnings from Continuing Operations | -74.55% | -11.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 32.73% | 41.48% | |||
| Net Income | -76.55% | -8.82% | |||
| EBIT | -37.09% | 26.06% | |||
| EBITDA | -29.21% | 26.69% | |||
| EPS Basic | -76.55% | -8.87% | |||
| Normalized Basic EPS | -41.61% | 35.80% | |||
| EPS Diluted | -76.37% | -9.30% | |||
| Normalized Diluted EPS | -41.65% | 35.23% | |||
| Average Basic Shares Outstanding | 0.02% | 0.05% | |||
| Average Diluted Shares Outstanding | 0.10% | 0.46% | |||
| Dividend Per Share | 12.07% | 1.20% | |||
| Payout Ratio | 3.19% | 0.13% | |||